Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. SPY

Go back to Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) Delayed: 28.11 -0.19 (0.67%)
Previous Close $28.30    52 Week High $37.39 
Open $27.97    52 Week Low $28.25 
Day High $28.18    P/E 17.04 
Day Low $27.83    EPS $1.65 
Volume 15,455,413       

Pfizer Inc. (NYSE: PFE) Delayed: 28.11 -0.19 (0.67%)
Previous Close $28.30    52 Week High $37.39 
Open $27.97    52 Week Low $28.25 
Day High $28.18    P/E 17.04 
Day Low $27.83    EPS $1.65 
Volume 15,455,413       

Sangamo Biosciences, Inc. (NASDAQ: SGMO) Delayed: 0.18 --0 (-0%)
Previous Close $0.18    52 Week High $9.91 
Open $0.18    52 Week Low $3.10 
Day High $0.18    P/E N/A 
Day Low $0.18    EPS $-0.48 
Volume 3,500